Home Cart Sign in  
Chemical Structure| 284461-73-0 Chemical Structure| 284461-73-0
Chemical Structure| 284461-73-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Sorafenib is a multi-kinase inhibitor that inhibits Raf-1 and B-RAF (IC50s = 6 and 22 µM, respectively), as well as the receptor tyrosine kinases VEGFR2, VEGFR3, PDGFRβ, FLT3, and c-Kit (IC50s = 90, 15, 20, 57, and 58 nM, respectively).

Synonyms: Bay 43-9006

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Marlhoux, Léna ; Arnaud, Alexandre ; Hervieu, Céline ; Makulyte, Gabriela ; Martinasso, Charlotte ; Mularoni, Angélique , et al.

Abstract: Casein kinase 2 (CK2) has emerged as a promising therapeutic target across a broad spectrum of malignancies, including pediatric and orphan cancers. The identification of a ligandable allosteric αD pocket on the CK2α subunit has enabled the development of bivalent inhibitors, which bind simultaneously to both the adenosine triphosphate (ATP) site and the allosteric pocket. Here, we report the discovery and pharmacological characterization of KDX1381, a structure-guided bivalent CK2α inhibitor with low-nanomolar potency and high selectivity, confirmed by cocrystal structures. In mice, KDX1381 suppressed CK2-driven tumor growth as a monotherapy and enhanced therapeutic efficacy when combined with vascular endothelial growth factor receptor (VEGFR) inhibitors or DNA-damaging agents in hepatocellular carcinoma and glioma models. These findings support bivalent CK2α inhibition as a differentiated therapeutic strategy with broad applicability in CK2-dependent cancers.

Alternative Products

Product Details of Sorafenib

CAS No. :284461-73-0
Formula : C21H16ClF3N4O3
M.W : 464.83
SMILES Code : O=C(NC)C1=NC=CC(OC2=CC=C(NC(NC3=CC=C(Cl)C(C(F)(F)F)=C3)=O)C=C2)=C1
Synonyms :
Bay 43-9006
MDL No. :MFCD06411450
InChI Key :MLDQJTXFUGDVEO-UHFFFAOYSA-N
Pubchem ID :216239

Safety of Sorafenib

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H360-H362-H372-H410
Precautionary Statements:P201-P202-P260-P263-P264-P270-P273-P280-P308+P313-P391-P405-P501
Class:9
UN#:3077
Packing Group:

Application In Synthesis of Sorafenib

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 284461-73-0 ]

[ 284461-73-0 ] Synthesis Path-Downstream   1~3

  • 1
  • [ 320-50-3 ]
  • [ 284461-73-0 ]
  • 2
  • [ 1129683-83-5 ]
  • [ 1209459-88-0 ]
  • [ 284461-73-0 ]
YieldReaction ConditionsOperation in experiment
96.7% The reaction bottle adding compound IV 31.35 g, cesium carbonate 46.33 g, cuprous chloride 2.84 g, 2,2,6,6-tetramethyl-3,5-heptyldiketone (0.0332 muM), 600 ml N,N-dimethyl-pyrrolidone, control in the 50 - 60 C stirring 30 min, then the compound is added V 24.47 g, stirring to reflux 2 h, TLC monitoring the completion of reaction. After the reaction is concentrated under reduced pressure, ethanol or recrystallization, to obtain the solid sorafenib (I) 42.62 g, the product yield is 96.7%, HPLC purity of 99.98%
  • 3
  • [ 611226-36-9 ]
  • [ 1129683-83-5 ]
  • [ 284461-73-0 ]
YieldReaction ConditionsOperation in experiment
96.3% at 132℃; (3) 4-[([chloro]-3-(trifluoromethyl) phenyl] amino}carbonyl) Amino] phenol (44.72 g, 6.6 mol) obtained in the step (2) was added (4-hydroxy-6-yl)pyridine-N-methyl-2-carboxamide (40.5 g, 5.25 mol) with a catalyst, followed by heating to effect etherification under controlled temperature conditions to generate 4- {4- [ ([4-chloro-3-(trifluoromethyl)phenyl)]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide (35.9g, 5.6 mol), yield 88.9%.
 

Historical Records

Categories